Physician profile
Marc J Meth
NPI 1508013301
$21,088.98
in general payments reported to CMS, 2019-2025
38 companies · $2,311 in 2025
The $2,311 reported for 2025 was more than what a typical Clinical & Laboratory Immunology (Allergy & Immunology) provider received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,015 · 2020: $1,793 · 2021: $1,256 · 2022: $2,956 · 2023: $2,424 · 2024: $2,334 · 2025: $2,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,669 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,669.07 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $5,463.25 | 2019 | |
| Genzyme Corporation | $2,464.29 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,150.81 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $1,488.49 | 2019-2023 | Xembify |
| Glaxosmithkline, LLC. | $1,148.01 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $1,094.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $997.68 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Novartis Pharmaceuticals Corporation | $886.98 | 2019-2025 | |
| Csl Behring | $799.24 | 2019-2025 | Hizentra, Haegarda |
| Pfizer INC. | $712.58 | 2019-2025 | |
| Abbvie INC. | $644.40 | 2021-2024 | |
| Aerin Medical INC. | $400.00 | 2024 | |
| Genentech USA, INC. | $310.60 | 2019-2025 | Xolair |
| Kaleo, INC. | $289.02 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $265.41 | 2020-2025 | Takhzyro, Cuvitru |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $224.64 | 2022-2025 | Ryaltris |
| Amgen INC. | $211.30 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $202.75 | 2019-2021 | |
| Globus Medical, INC. | $159.58 | 2024 | Xlif |
| Ars Pharmaceuticals Operations, INC. | $144.49 | 2025 | Neffy |
| Alk-Abello, INC | $141.25 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.84 | 2019-2021 | |
| Bio Products Laboratory USA, INC. | $113.28 | 2019-2023 | Coagadex, Gammaplex |
| Sanofi-Aventis U.S. LLC | $104.09 | 2019 | |
| Blueprint Medicines Corporation | $96.49 | 2023-2024 | Ayvakit |
| Shire North American Group INC | $66.61 | 2019 | |
| Octapharma USA, INC. | $65.57 | 2020-2023 | Cutaquig |
| Galderma Laboratories, L.P. | $47.85 | 2025 | Nemluvio |
| Incyte Corporation | $44.17 | 2021-2023 | Opzelura |
| Merck Sharp & Dohme LLC | $42.62 | 2021-2023 | |
| Horizon Therapeutics Plc | $41.90 | 2019 | |
| Phadia US INC. | $33.11 | 2021-2023 | Immunocap |
| Arcutis Biotherapeutics, INC. | $23.11 | 2025 | Zoryve |
| Leo Pharma INC. | $22.93 | 2025 | Adbry |
| Pharming Healthcare, INC. | $22.65 | 2025 | Ruconest |
| Organon LLC | $21.04 | 2025 | Vtama |
| Novo Nordisk INC | $17.15 | 2023 | Wegovy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Meth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.